It’s time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN.
CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population.
At CuraSen, we are rethinking the therapeutic approach to treatment of neurodegenerative diseases—and advancing a concept based on restoring a key functionality to a pathway lost early in the degenerating brain. This pathway emanates from the locus coeruleus (LC), site of the earliest pathology seen in these diseases – perhaps the ‘hypocenter’ of neurodegeneration.
We began clinical testing of our hypothesis in 2019 using established drugs from other therapeutic areas, which has informed our development program and helped advance our first new chemical entity, CST-2032, to the clinic in September 2020.
CuraSen has assembled an impressive team, deeply experienced in the neuroscience, pharmacology and clinical development core to its approach, as well as top tier investor backing, including New Leaf Venture Partners, Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Pappas Capital.
Company Details
- Employees
- 20
- Founded
- -
- Address
- 930 Brittan Ave,
- Phone
- (650) 475-2842
- in****@****Sen.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.curasen.com
- Keywords
- Parkinson’s Disease, Alzheimer’s Disease, Locus Coeruleus, Neurodegeneration, Neuroinflammation, Neurometabolism, Cerebral Blood Flow.
- HQ
- San Carlos, California
Curasen Therapeutics, Inc. Questions
Curasen Therapeutics, Inc.'s helpline number is (650) 475-2842
Curasen Therapeutics, Inc.'s website is http://www.curasen.com
Curasen Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/curasen
Curasen Therapeutics, Inc. has
20 employees.
View email and phone details for 20
employees at Curasen Therapeutics, Inc..
Curasen Therapeutics, Inc.'s industry is
Biotechnology Research
Curasen Therapeutics, Inc.'s top competitors are
Glycomine Inc.,
Biorchestra Co., Ltd.,
Delphia Therapeutics,
Emoty Ai,
Ptc Therapeutics, Inc.,
Gate Neurosciences,
Tiziana Life Sciences,
Supernus Pharmaceuticals, Inc.,
Mindmaze,
Complement Therapeutics.
Curasen Therapeutics, Inc.'s support email address is info@CuraSen.com
Curasen Therapeutics, Inc.'s categories are Biotechnology Research
Curasen Therapeutics, Inc.'s founding year is 2017
